BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34783301)

  • 1. Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors.
    Kopeva KV; Grakova EV; Shilov SN; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Acta Cardiol; 2022 Nov; 77(9):805-814. PubMed ID: 34783301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anthra-cycline-Induced Cardiotoxicity: the Role of Genetic Predictors].
    Kopeva KV; Grakova EV; Shilov SN; Popova AA; Berezikova EN; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Kardiologiia; 2023 May; 63(4):22-28. PubMed ID: 37165991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
    Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
    Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction.
    Grakova EV; Shilov SN; Kopeva KV; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Cardiology; 2021; 146(3):315-323. PubMed ID: 33596565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
    Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.
    Bisoc A; Ciurescu D; Rădoi M; Tântu MM; Rogozea L; Sweidan AJ; Bota DA
    Am J Ther; 2020; 27(2):e142-e150. PubMed ID: 30648987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
    Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
    Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
    Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
    J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
    Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
    Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
    Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
    Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines.
    Kouloubinis A; Sofroniadou S; Panoulas VF; Makaritsis K; Revela I; Karavolias G; Voudris V; Adamopoulos S
    Int J Cardiol Heart Vasc; 2015 Mar; 6():85-90. PubMed ID: 28785633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction.
    Kopeva KV; Grakova EV; Shilov SN; Berezikova EN; Bobyleva ET; Teplyakov AT
    Heart Vessels; 2023 Oct; 38(10):1256-1266. PubMed ID: 37310463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic role of p53 gene polymorphism in risk assessment of anthracycline-induced cardiotoxicity].
    Shilov SN; Teplyakov AT; Popova AA; Berezikova EN; Neupokoeva MN; Grakova EV; Valeeva AM; Tuleutaev SM
    Kardiologiia; 2019 Aug; 59(7S):15-22. PubMed ID: 31441737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?
    Grakova EV; Shilov SN; Kopeva KV; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Int J Cardiol; 2022 Mar; 350():55-61. PubMed ID: 35007649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
    de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.